Finance

Lists
Why is I1DX34 up 2.62%?
Dive Deeper
I1DX34:BVMF
Idexx Laboratories Inc Bdr
R$816.36
+2.62%
(+20.83) 1D
Nov 19, 4:02:35 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for I1DX34...
Open
R$816.36
High
R$816.36
Low
R$816.36
Mkt. cap
54.35B
Avg. vol.
3.00
Volume
1.00
52-wk high
R$816.36
52-wk low
R$509.99
Shares outstanding
78.79M
No. of employees
11K
Open
R$816.36
High
R$816.36
Low
R$816.36
Mkt. cap
54.35B
Avg. vol.
3.00
Volume
1.00
52-wk high
R$816.36
52-wk low
R$509.99
Shares outstanding
78.79M
No. of employees
11K
News stories
From web sources and news partners
Profile
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions. In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO. In 2025, IDEXX estimated annual sales between $4.21 billion and $4.28 billion, with total quarterly revenue exceeding $1 billion. Wikipedia
About Idexx Laboratories Inc Bdr
CEOJay Mazelsky
Employees11K
FoundedDec 19, 1983
HeadquartersWestbrook, Maine, United States
SectorHealth Care
IndustryMedical device
Websiteidexx.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.09B
1.14B
1.22B
1.21B
Cost of goods sold
432.46M
418.08M
437.50M
449.94M
Cost of revenue
432.46M
418.08M
437.50M
449.94M
Research and development expenses
66.83M
65.79M
65.43M
68.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
266.68M
294.36M
288.09M
293.13M
Operating expense
333.51M
360.15M
353.52M
361.95M
Total operating expenses
765.97M
778.23M
791.02M
811.89M
Operating income
324.60M
362.59M
425.57M
402.35M
Other non operating income
-
-
-
-
EBT including unusual items
306.98M
355.44M
417.22M
399.32M
EBT excluding unusual items
315.98M
355.44M
415.99M
395.86M
Income tax expense
58.79M
77.00M
78.81M
82.18M
Effective tax rate
19.15%
21.66%
18.89%
20.58%
Other operating expenses
-
-
-
-
Net income
248.19M
278.45M
338.41M
317.14M
Net profit margin
22.76%
24.41%
27.82%
26.12%
Earnings per share
3.08
3.47
4.27
4.01
Interest and investment income
587.00K
597.00K
606.00K
967.00K
Interest expense
-9.21M
-7.74M
-10.18M
-7.46M
Net interest expenses
-8.62M
-7.14M
-9.58M
-6.49M
Depreciation and amortization charges
-
-
-
-
EBITDA
363.33M
400.27M
466.62M
442.91M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps